Zomato founder and CEO Deepinder Goyal has announced the launch of a $25 million research fund, entirely self-financed, under his initiative Continue Research — aimed at backing scientists exploring the fundamental biology of human ageing.
In a detailed post on X (formerly Twitter), Goyal said the fund will offer grants to researchers worldwide who “dare to ask simpler questions” in biology — those that challenge existing complex models of ageing.
About Continue Research
Continue began two years ago as a personal research effort inspired by the idea that if the human body is a system, it must have leverage points — simple biological mechanisms that can significantly influence how humans age.
Goyal said his team has been investigating a hypothesis that could “fundamentally change our understanding of biology and ageing” if proven true.
Two funding tracks for global researchers
According to the initiative’s website, the Continue Fund will support two categories of projects:
- Moonshots: Grants between $50,000–$250,000 for high-risk, early-stage ideas that could reshape scientific understanding.
- Deep Dives: Grants between $250,000–$2 million for long-term projects (1–3 years) that aim to validate or disprove promising hypotheses.
Open-source science approach
A key requirement for funding under Continue Research is that all data, protocols, and results — including failed experiments — must be made open source and accessible to the public. The fund will not require prior publications or impose bureaucratic oversight.
Goyal’s vision: “Not defeating death, but improving life”
Goyal clarified that the goal is not immortality, but rather extending healthy human function long enough to enable future generations to make more sustainable, long-term decisions.
“The goal is to extend healthy human function long enough that humans stop making short-term decisions. This work will likely take decades to bear fruit. The primary beneficiaries will be generations that come after us, not us,” he wrote.
Continue Research defines itself as “a research team and seed fund for the next phase of human existence,” positioning the initiative at the intersection of biology, longevity, and open scientific collaboration.
